🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Paul A. Bunn

University of Colorado Health

ORCID: 0000-0003-0518-5959
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile
7.4Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model

The American Journal of Pathology(2005)10.1016/s0002-9440(10)61257-6
Top 2%
7.4DataRank
Top 2%314 citations

Lori Dwyer-Nield, Laura Zerbe, Stacy A. Blaine, Zeng Chan, Paul A. Bunn +14 more

Papers

Driven by 12 papers — median percentile 98. Top paper: “Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model”.

Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model

The American Journal of Pathology(2005)10.1016/s0002-9440(10)61257-6
Top 2%
7.4DataRank
Top 2%314 citations

Lori Dwyer-Nield, Laura Zerbe, Stacy A. Blaine, Zeng Chan, Paul A. Bunn +14 more

Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment

JAMA Network Open(2022)10.1001/jamanetworkopen.2022.27211
N/A
1.1DataRank · unranked
29 citations

Chih–Yuan Hsu, Lynne D. Berry, Paul A. Bunn, Yu Shyr, Emily Pei-Ying Lin

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.01.005
N/A
0.922DataRank · unranked
466 citations

Sanja Đačić, Ignacio I. Wistuba, Lynette M. Sholl, Prasad S. Adusumilli, Lukas Bubendorf +38 more

Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.11.001
N/A
0.601DataRank · unranked
54 citations

Noy Meshulami, Alessandro Russo, Florian Krammer, Adolfo Garcı́a-Sastre, Philip C. Mack +14 more

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer

Journal of Thoracic and Cardiovascular Surgery(2022)10.1016/j.jtcvs.2022.10.007
N/A
0.568DataRank · unranked
43 citations

Alan Nicholas, G. Alexander Patterson, Salama N. Waqar, Eric M. Toloza, Eric B. Haura +24 more

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer

Journal of Clinical Investigation(2023)10.1172/jci160330
N/A
0.464DataRank · unranked
21 citations

Ruichen Rong, Donghan M. Yang, Junya Fujimoto, Justin A. Bishop, Shirley Yan +15 more

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

Cancer Cell(2022)10.1016/j.ccell.2022.04.012
N/A
0.442DataRank · unranked
18 citations

Jorge Gómez, Ananda M. Rodilla, Juan Manuel Carreño, Chih–Yuan Hsu, Christian Rolfo +43 more

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00510
N/A
0.208DataRank · unranked
3 citations

Jose M. Pacheco, Anastasios Dimou, W. Thomas Purcell, Candice Rossi, Paul A. Bunn +4 more

Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer

Vaccines(2024)10.3390/vaccines12070713
N/A
0.104DataRank · unranked
1 citations

Chih–Yuan Hsu, Ananda M. Rodilla, Jorge Gómez, Jazz Cagan, Yuanhui Huang +19 more

Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.08.010
N/A
0DataRank · unranked
1 citations

Chih–Yuan Hsu, Jeng-Fong Chiou, Lynne D. Berry, Leora Horn, Paul A. Bunn +5 more

The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations

Lung Cancer(2024)10.1016/j.lungcan.2024.108040
N/A
0DataRank · unranked
10 citations

Dexiang Gao, Alexander Watson, M Sakamoto, Yunan Nie, A.J. Gibson +13 more

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100637
N/A
0DataRank · unranked
8 citations

Alyse Staley, Yunan Nie, M Sakamoto, Margaret Stalker, James Jurica +17 more